Trial reportAddiction (Abingdon, England)2014
Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial.
Trial report in Addiction (Abingdon, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05039554 (Randomized Trial of Acceptance and Commitment Therapy), which is not on this map. Cited by 32 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial of Acceptance and Commitment Therapy (ACT) and a Care Management App in Primary Care-based Buprenorphine Treatment
Who cites it
32 citing papers in PubMed, 7 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Addressing tobacco use in the context of opioid use disorder: A systematic review of smoking cessation interventions.The American journal on addictions · 2026Pooled it
- Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024.Journal of Korean medical science · 2025Guideline
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.Drug and alcohol dependence · 2021Pooled it
- Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders.The Cochrane database of systematic reviews · 2016Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2016Pooled it
- Effect of brief nicotine corrective messaging on nicotine beliefs in persons who use opioids.Experimental and clinical psychopharmacology · 2022Trial
- Timing of smoking cessation treatment integrated into outpatient treatment with medications for opioid use disorder: Feasibility trial.Journal of substance abuse treatment · 2022Trial
- Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.Journal of substance abuse treatment · 2021Trial
- The impact of menthol cigarette use on quit attempts and abstinence among smokers with opioid use disorder.Addictive behaviors · 2021Trial
- Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial.Addiction (Abingdon, England) · 2021Trial
- Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement.Journal of substance abuse treatment · 2019Trial
- Cigarette Smoking Cessation Intervention for Buprenorphine Treatment Patients.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Trial
- Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms.Addiction (Abingdon, England) · 2017Trial
- Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial.Addiction (Abingdon, England) · 2016Trial
- Barriers to Telephone Quitline Use Among Methadone-Maintained Smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Trial
- Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics.Addiction science & clinical practice · 2014Trial
- Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use.Journal of psychoactive drugsTrial
- Development and evaluation of a quitline intervention commenced within an Australian smoke-free residential AOD withdrawal service.PEC innovation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
aimsTo test the efficacy and safety of varenicline as an aid to smoking cessation in methadone-maintained smokers.
designMulticenter, randomized, double-blind, placebo-controlled trial with random assignment to 12 weeks of varenicline 1 mg twice daily (n = 57) or matched placebo (n = 55), with in-person and telephone counseling.
settingUrban methadone programs in the Bronx, New York City, New York, USA.
participantsMethadone maintenance patients, smoking ≥5 cigarettes/day, interested in quitting, stable in methadone treatment, without current Axis I psychiatric disorders, suicidal ideation or recent suicide attempts. MEASUREMENTS: Seven-day point prevalence abstinence verified by expired carbon monoxide (CO) < 8 parts per million at week 12 (primary outcome); carbon monoxide (CO)-verified abstinence, cigarettes/day, incident Axis I psychiatric illness, suicidal ideation or serious adverse events (SAEs) at weeks 2, 4, 8, 12 or 24 (secondary outcomes).
findingsBaseline demographic, smoking and clinical factors were similar between groups. Retention at 24 weeks was 90%. Subjects receiving varenicline were more likely than those receiving placebo to achieve abstinence (10.5 versus 0%, P = 0.03; effect size 10.5%, 95% confidence interval (CI) = 4.4-19.3%) and to reduce smoking (median five versus two cigarettes/day, P < 0.001) at 12 weeks. These effects were not maintained after drug treatment ceased. Incident psychiatric illness (OR= 0.84, 95% CI = 0.16, 4.4) and suicidality [odds ratio (OR) = 0.88, 95% CI 0.2, 3.9] were not different between groups. There were no psychiatric or cardiac SAEs.
conclusionsVarenicline can aid short-term smoking abstinence in methadone-maintained smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.